We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.50 | -0.66% | 1,435.00 | 1,432.50 | 1,433.00 | 1,440.50 | 1,431.50 | 1,439.00 | 5,985,621 | 16:35:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 31.38B | 2.58B | 0.6212 | 23.06 | 59.88B |
From Feb 2020 to Feb 2025
By Jaime Llinares Taboada
GlaxoSmithKline PLC said Tuesday that new preclinical studies demonstrated that its sotrovimab antibody retains activity against the Omicron coronavirus variant.
The British pharmaceutical major said sotrovimab retains in vitro activity against the full known Omicron spike protein.
These findings build on initial preclinical data provided last week, showing that the antibody retains activity against all tested variants of concern.
"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO [World Health Organization], and we look forward to discussing these results with regulatory authorities around the world," Chief Scientific Officer Hal Barron said.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT
(END) Dow Jones Newswires
December 07, 2021 02:36 ET (07:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
